The case for early detection.
Early detection represents one of the most promising approaches to reducing the growing cancer burden. It already has a key role in the management of cervical and breast cancer, and is likely to become more important in the control of colorectal, prostate and lung cancer. Early-detection research has recently been revitalized by the advent of novel molecular technologies that can identify cellular changes at the level of the genome or proteome, but how can we harness these new technologies to develop effective and practical screening tests?
Etzioni
Ruth
R
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, USA. retzioni@fhcrc.org
Urban
Nicole
N
Ramsey
Scott
S
McIntosh
Martin
M
Schwartz
Stephen
S
Reid
Brian
B
Radich
Jerald
J
Anderson
Garnet
G
Hartwell
Leland
L
D014408:Biomarkers, Tumor / Q000032:analysis; D002986:Clinical Trials as Topic; D005819:Genetic Markers; D006801:Humans; D008403:Mass Screening / Q000191:economics / Q000379:methods*; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000517:prevention & control*; D012107:Research Design; D016019:Survival Analysis; D014481:United States
D014408:Biomarkers, Tumor; D005819:Genetic Markers